Did you know that HMOs are not only important for healthy infant development, but can also serve as a prebiotic for adults, contribute to combating allergies and diabetes and enhance the effectiveness of vaccines and antibiotics? And did you know that the main reason they are not used more often is that they have been so hard to come by... until now!
Background
Technology
acib has described and optimized several enzymes for regioselective glycosyl transfer and glycosidic modifications. In a recent project, acib has developed modular enzymatic steps that can be integrated into cascade reactions to produce a variety of specific HMOs in E. coli. This platform technology was demonstrated for the production of 6’-sialyl-lactose, 3’-sialyl-lactose and 2’-fucosyl-lactose and can be used for many other HMOs. acib also has experience in analysis, purification and upscaling of HMOs.
Offer
acib offers a unique opportunity for natural HMO-production using enzymatic cascades (and metabolic engineering). acib provides knowhow in bioprocess technology design, ensuring seamless transition from laboratory to industrial-scale production. Intellectual property (IP) generated during the collaboration can be transferred to you, our investor/industrial partner. acib has 30+ years of experience and has worked successfully with >250 industry partners.
acib offers you the opportunity to establish cost-efficient bioproduction of valuable HMOs.